• Resistance mechanisms in cancer cells
• Early clinical oncologic trials (phase I)
• Studies concerning prognostic and predictive tumour markers in breast and colorectal cancer
• Clinical trials and treatment of breast and colorectal cancer
• Cardiotoxicity of cytotoxic and targeted treatment
• Response evaluation in oncology

Ongoing research includes 1) oncologic phase I trials, 2) predictive biomarkers  (inclusive mikroRNA profiles) for sensitivity of chemotherapy and targeted treatment (irinotecan and cetuximab) in colorectal cancer patients, 4) predictive biomarkers in breast cancer 4) phase II studies of irinotecan in breast cancer in collaboration with Danish Breast Cancer Group (DBCG), 5) phase II studies concerning intrahepatic chemotherapy and 6) investigation of trastuzumab, anthracycline and 5-fluorouracil cardiotoxicity.

Exams, registrations and academic degrees

1980: Final university examination as physician from University of Copen¬hagen, June 1980.

Internship completed (Full registration as physici¬an), January 1984.

Certificate from the Danish National Board of Health to be designated as specialist in oncology, February 1995.

Ph.D., University of Copenhagen, title of thesis: “Daunorubicin resistant Ehrlich ascites tumor cells. Resistan¬ce, P-glycoprotein ex¬pression, steady state ac¬cumula-tion and reversal”, April 1994.

Doctor of Medical Science (DMSc), University of Copenhagen, title of thesis: “Mechanisms and functional aspects of multidrug resistance in Ehrlich ascites tumour cells”, November 2004.

Appointments

Senior consultant, Department of Oncology, Herlev Hospital, since 1998. Professor in Clinical Oncology, SUND, KU, since 2010

Other activities

Administration

Head of Clinical Research Unit, Department of Oncology, Rigshospitalet 1996- 1998.

Head of Clinical Research Unit, Department of Oncology, Herlev Hospital, since1999.

Head of Unit for Experimental Chemotherapy, Department of Oncology, Herlev Hospital since 2004.

Head of Centre for Cancer Research, Department of Oncology, Herlev Hospital, since 2008.

Responsible for research, Department of Oncology, Herlev Hospital, since 2008.

Participation in council, boards, and committees

Member of “The Ethical Committee for Copenhagen County”, 2002-2007.

Member of “Medical board, Danish Breast Cancer Group”, since 1998.

Member of “The Danish National Coordination Group for Experimental Cancer Treatment (NKU)”, since 2004.

Appointed member of “National Society for Evaluation of Cancer Drugs (UVKL)”, 2008-2012.

Appointed member of ”(KoordineringsRådet for Ibrugtagning af Sygehusmedicin (KRIS)”, since October 2012.

Member of Nordic NECT, nordic phase I trial collaboration since 2010.  

Expert-evaluator, European Commission, Framework Programme 7, 2012-2013.

Extern reviewer The Research Council of Norway, 2013.

Awards

Højesteretssagfører Kaj Bunch-Jensen og Allis Bunch-Jensens hæderslegat, 2005.